Onset Therapeutics Announces Release of ANESTAFOAM®
Study Results Demonstrate that (Lidocaine 4% Foam) Reduces Pain Associated with Common Dermatologic Procedures
Cumberland, RI -- May 4 – Results from an open label study assessing the reduction in Procedure-Associated Pain with the use of a lidocaine 4% foam (ANESTAFOAM® ) were published in the April issue of The Journal of Clinical and Aesthetic Dermatology. Evidence from this study suggests that ANESTAFOAM® (indicated for the relief of pain associated with minor cuts, burns, abrasions, sunburn, and insect bites) may be acceptable to patients and clinicians for the safe and effective reduction of pain associated with cosmetic dermatologic laser procedures.
Primary endpoints for this open label study were clinician and patient assessments of procedural pain intensity, recorded on a visual analog scale (VAS) for both treated and untreated areas. Secondary objectives included clinician indication of overall satisfaction and ease of foam application on a five point Likert scale and the patients’ subjective assessment of increased comfort associated with ANESTAFOAM® during the procedures. Of the patients that completed the study, 70% underwent laser hair removal using a 755nm alexandrite laser on various body parts (four underarms, two legs, one neck and jaw), two participated in a 1450nm diode laser session to correct facial acne scarring and one other patient experienced a facial IPL treatment for telangiectasia and photodamage correction.
It is widely accepted by practicing dermatologists that product vehicle is extremely important when determining the efficacy, side effect profile and patient compliance of topical products. ANESTAFOAM® was designed with an advanced semi-solid, emollient micro-emulsion formulation to improve the ability of topically applied lidocaine to penetrate the skin without the messiness associated with cream or ointments. In addition, ANESTAFOAM® is delivered in Delevo™ foam technology which is moisturizing, alcohol-free, easy to spread over large areas of the body, and leaves no messy residue after absorption into the skin. All of these attributes can lead to higher patient acceptability ratings and patient compliance.
ANESTAFOAM® is indicated for the relief of pain associated with minor cuts, burns, abrasions, sunburn, and insect bites. For external use only. Application of ANESTAFOAM® to larger areas, or more frequently than recommended, could result in excessive absorption of lidocaine and result in serious adverse effects. Although uncommon, side effects may occur and, if persistent, should be reported to your healthcare provider. The most common side effects are irritation, redness, itching, and rash. Any unusual effects such as blurred vision, dizziness or drowsiness, difficulty breathing, trembling, chest pain, or irregular heartbeat, should be immediately reported to a health care professional. For more product information, visit http://www.onsettx.com/anestafoam.html.
About Onset Therapeutics
Onset Therapeutics is a specialty pharmaceutical company focusing on the development and commercialization of novel, patent protected topical products for the treatment of skin and skin disorders. The company’s capabilities include Formulation Development, Intellectual Property Development; Clinical Development; GMP Manufacturing; and Product Commercialization. For more information, please visit the company’s website at www.onsettx.com.